Zimmer Biomet reported adjusted EPS of $2.09 and net sales of $2.09 billion, both surpassing consensus estimates, but shares dipped in premarket trading.
All business segments grew, with notable product launches and margin expansion. The company raised its 2026 adjusted EPS guidance to $8.40-$8.55 and expects 2.5-4.5% revenue growth.
Despite strong results, investor reaction was negative. Zimmer Biomet’s performance is compared to peers like Globus Medical and Intuitive Surgical, which also recently exceeded earnings expectations.
With record earnings but a falling stock, what hidden detail is worrying investors about Zimmer Biomet's future profitability?
Is Zimmer Biomet's high-growth S.E.T. division strong enough to offset future challenges in its core knee and hip markets?
How is Zimmer Biomet adapting its sales and technology for the growing, cost-sensitive ambulatory surgical center market?
Two years after a catastrophic IT failure, are Zimmer Biomet's operations truly resilient against future supply chain disruptions?
As robotic surgery becomes standard, is the ROSA platform innovating fast enough to outpace its key competitors?